前列腺癌调强放疗与三维适形放疗后第二原发癌风险比较(2002-2015)
该回顾性队列研究基于Medicare与SEER链接数据库(2002-2015),纳入65 235例2年生存者和45 811例5年生存者,评估调强放疗(IMRT)与三维适形放疗(3DCRT)后第二原发癌风险。结果显示IMRT与第二血液系统肿瘤风险无关;5年生存者中IMRT vs 3DCRT第二实体瘤总体HR为0.91(95%CI 0.83-0.99),该负相关仅限于较早诊断年份。
要点
- IMRT与3DCRT相比,第二血液系统肿瘤风险总体及特定类型均无关联。
- 5年生存者中IMRT vs 3DCRT第二实体瘤总体HR为0.91(95%CI 0.83-0.99)。
- IMRT与第二实体瘤的负相关仅限于2002-2005年诊断者,2006-2010年无统计学显著关联。
核心结论
- 这项大型人群队列研究结果提示,前列腺癌IMRT与第二原发癌(实体瘤或血液系统肿瘤)风险升高无关,任何负相关可能与治疗日历年有关。
研究设计与样本
- 回顾性队列研究,使用Medicare理赔与SEER癌症登记链接数据库(2002-2015),纳入2002-2013年诊断的首发非转移性前列腺癌、年龄66-84岁、并在诊断后第一年内接受放疗(IMRT和/或3DCRT,不含质子治疗)的男性患者。
- 数据分析时间为2022年1月至2022年6月。
- 暴露为根据Medicare理赔确定的IMRT与3DCRT。
- 主要结局为前列腺癌诊断后至少2年发生的后续血液系统肿瘤,或诊断后至少5年发生的后续实体瘤。
主要发现
- 研究纳入65 235例2年第一原发前列腺癌生存者(中位[范围]年龄72[66-82]岁;82.2%为白人)和45 811例5年生存者(中位[范围]年龄72[66-79]岁;82.4%为白人)。
- 2年生存者(中位[范围]随访4.6[0.003-12.0]年)中诊断1107例第二血液系统肿瘤(IMRT 603例;3DCRT 504例),放疗类型与第二血液系统肿瘤总体或所评估的任何特定类型均无关联。
- 5年生存者(中位[范围]随访3.1[0.003-9.0]年)中2688例诊断第二原发实体瘤(IMRT 1306例;3DCRT 1382例),IMRT vs 3DCRT的总体HR为0.91(95%CI 0.83-0.99)。
- 该负相关仅限于较早的前列腺癌诊断日历年(2002-2005年HR=0.85,95%CI 0.76-0.94;2006-2010年HR=1.14,95%CI 0.96-1.36),结肠癌呈现相似模式(2002-2005年HR=0.66,95%CI 0.46-0.94;2006-2010年HR=1.06,95%CI 0.59-1.88)。
临床怎么用
- 原文未据此给出推荐,结论为IMRT与第二原发癌风险升高无关,任何负相关可能与治疗日历年有关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Compared with 3-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT) can spare nearby tissue but may result in increased scatter radiation to distant normal tissue, including red bone marrow. It is unclear whether second primary cancer risk varies by radiotherapy type. OBJECTIVE: To evaluate whether radiotherapy type (IMRT vs 3DCRT) is associated with second primary cancer risk among older men treated for prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study of a linked database of Medicare claims and Surveillance, Epidemiology, and End Results (SEER) Program population-based cancer registries (2002-2015), male patients aged 66 to 84 diagnosed with a first primary nonmetastatic prostate cancer from 2002 to 2013, as reported to SEER, and who received radiotherapy (IMRT and/or 3DCRT without proton therapy) within the first year following prostate cancer were identified. The data were analyzed from January 2022 through June 2022. EXPOSURE: Receipt of IMRT and 3DCRT, based on Medicare claims. MAIN OUTCOMES AND MEASURES: The association between radiotherapy type and development of a subsequent hematologic cancer at least 2 years after prostate cancer diagnosis or a subsequent solid cancer at least 5 years after prostate cancer diagnosis. Hazard ratios (HRs) and 95% CIs were estimated using multivariable Cox proportional regression. RESULTS: The study included 65 235 2-year first primary prostate cancer survivors (median [range] age, 72 [66-82] years; 82.2% White patients) and 45 811 5-year survivors with similar demographic characteristics (median [range] age, 72 [66-79] years; 82.4% White patients). Among 2-year prostate cancer survivors (median [range] follow-up, 4.6 [0.003-12.0] years), 1107 second hematologic cancers were diagnosed (IMRT, 603; 3DCRT, 504). Radiotherapy type was not associated with second hematologic cancers overall or any specific types evaluated. Among 5-year survivors (median [range] follow-up, 3.1 [0.003-9.0] years), 2688 men were diagnosed with a second primary solid cancer (IMRT, 1306; 3DCRT, 1382). The overall HR for IMRT vs 3DCRT was 0.91 (95% CI, 0.83-0.99). This inverse association was restricted to the earlier calendar year period of prostate cancer diagnosis (HR2002-2005 = 0.85; 95% CI, 0.76-0.94; HR2006-2010 = 1.14; 95% CI, 0.96-1.36), with a similar pattern observed for colon cancer (HR2002-2005 = 0.66; 95% CI, 0.46-0.94; HR2006-2010 = 1.06; 95% CI, 0.59-1.88). CONCLUSIONS AND RELEVANCE: The results of this large, population-based cohort study suggest that IMRT for prostate cancer is not associated with an increased risk of second primary cancers, either solid or hematologic, and any inverse associations may be associated with calendar year of treatment.
引用
- Pithadia KJ, Advani PG, Citrin DE, et al. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015. JAMA Oncol. 2023. PMID: 37289449. doi:10.1001/jamaoncol.2023.1638
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。